IUS Combined With VAT Predicts Anti-TNF-α Efficacy in Patients With IBD: a Prospective Study

Launched by THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · Dec 2, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to predict how well a specific treatment, called anti-TNF-α therapy, will work for patients with Inflammatory Bowel Disease (IBD). IBD includes conditions like Crohn's disease and ulcerative colitis, which can cause inflammation in the intestines and lead to various health issues. The researchers want to see if using intestinal ultrasound (IUS) along with measuring visceral adipose tissue (VAT)—a type of fat in the body—can help identify which patients are likely to respond well to this treatment. This could lead to more personalized treatment plans for patients with IBD.

To be eligible for the study, participants must be between 18 and 80 years old and have been newly diagnosed or are experiencing a relapse of active IBD. They should be planning to start anti-TNF-α therapy within a month after their initial examination. However, individuals with certain medical conditions or a history of specific surgeries will not be included. If you join the study, you'll undergo tests to gather information on your condition and how your body responds to the treatment, which could help improve future care for others with IBD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years and ≤ 80 years;
• • Patients with newly diagnosed or relapsed active IBD;
• • Anti-TNF-α monotherapy is proposed to be applied within 1 month after baseline endoscopy;
• • No history of abdominal surgery;
• • Clearly understand, voluntarily participate in the study, and sign an informed consent form.
• Exclusion Criteria:
• • Contraindications to anti-TNF-α therapy: allergy, active tuberculosis or other active infections, moderate-to-severe heart failure (NYHA grade III/IV), demyelinating lesions of the nervous system, live vaccination within the last 3 months, pregnancy and lactation;
• • Patients with a history of extensive colectomy or recent proposed colectomy, history of colonic mucosal dysplasia;
• • Hypersensitivity to the components of SonoVue contrast media.